Abstract:
Objective To analyse the clinical effect of cotransplantation of haploidentical hematopoietic stem cells and umbilical cord mesenchymal stem cells (UC-MSCs) for patients with severe aplastic anemia (SAA).
Methods Clinical data about 27 patients with haploidentical stem cells transplantation (haplo-HSCT) in our center from January 2007 to December 2013 were summarized. The engraftment, graft-versus-host disease (GVHD), overall survival (OS), disease/progression-free survival (PFS) and relapse after 2 years were observed.
Results All patients given MSCs showed sustained hematopoietic engraftment without any adverse UC-MSC infusion-related reaction. The median times of transplantation of neutrophil＞ 0.50×10
9/L and platelet＞ 20×10
9/L engraftment were 12.0 days (8-21 days) and 14.0 days (10-26 days), respectively. Grade Ⅱ to Ⅳ and Ⅲ/Ⅳ aGVHD was observed in 11 of 27 patients (40.7%) and 6 of 27 cases (22.2%), respectively. Chronic GVHD was observed in 13 of 26 patients (50.0%) and was extensive in 4 patients (15.4%). The probability that patients would attain 2-years overall survival (OS) was 76.3%.
Conclusion Cotransplantation of haploidentical hematopoietic stem cells and UC-MSCs has good treatment effect to patients with SAA without HLA-identical sibling donors or unrelated donors, which is a feasible salvage approach.
下载: